Genetic testing for breast and ovarian cancer susceptibility: A family experience

Journal of Midwifery and Women's Health

Volumn 49, Issue 3, 2004, Pages 210-219

  van Riper, Marcia ^a   McKinnon, Wendy C ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NONE

Author keywords

Breast and ovarian cancer susceptibility; Genetic testing; Management options

Indexed keywords

ORAL CONTRACEPTIVE AGENT; TAMOXIFEN;

BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; ETHICS; EXPERIENCE; FAMILIAL CANCER; FAMILY; FEMALE; GENETIC SCREENING; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; HUMAN; MIDWIFE; OVARY CANCER; PATIENT CARE; PRIORITY JOURNAL; REVIEW;

EID: 2342518103     PISSN: 15269523     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmwh.2004.01.021     Document Type: Article

References (75)

1. Wooster R. Weber B.L. Breast and ovarian cancer N Engl J Med 348 2003 2339-2347
2. Hallowell N. Foster C. Eeles R. Ardern-Jones A. Murday V. Watson M. Balancing autonomy and responsibility: The ethics of generating and disclosing genetic information J Med Ethics 29 2003 74-83
3. Lerman C. Psychological aspects of genetic testing: Introduction to the special issue Health Psychol 16 1997 3-7
4. Burgess M.M. d'Aincourt-Canning L. Genetic testing for hereditary disease: Attending to relational responsibility J Clin Ethics 12 2001 361-372
5. Finkler K. Skrzynia C. Evans J.P. The new genetics and its consequences for family, kinship, medicine and medical genetics Soc Sci Med 57 2003 403-412
6. Forrest K. Simpson S.A. Wilson B.J. van Teijlingen E.R. McKee L. Haites N. et al. To tell or not to tell: Barriers and facilitators in family communication about genetic risk Clin Genet 64 2003 317-326
7. Green J. Richards M. Murton F. Statham H. Hallowell N. Family communication and genetic counseling: The case of hereditary breast and ovarian cancer J Genet Couns 1997 45-61
8. Juengst E.T. Genetic testing and the moral dynamics of family life Public Understand Sci 8 1999 193-205
9. Lancaster J.M. Wiseman R.W. Berchuck A. An inevitable dilemma: Prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene Obstet Gynecol 87 1996 306
10. Thomson E. Ethical, legal, social, and policy issues in genetics In: Lashley F.R. (Ed.), The genetics revolution: Implications for nursing 1997 15-26 American Academy of Nursing Washington (DC)
11. Burke W. Emery J. Genetics education for primary-care providers Nat Rev Genet 3 2002 561-566
12. Greendale K. Reed P. Empowering primary care health professionals in medial genetics: How soon? How fast? How far? Am J Med Genet 106 2001 223-232
13. Hetteberg C. Prows C.A. Deets C. Monsen R. Kenner C. National survey of genetics content in basic nursing preparatory programs in the United States Nurs Outlook 47 1999 168-174
14. Wulfsberg E.A. The impact of genetic testing on primary care: Where's the beef? Am Fam Physician 61 2000 971-972
15. Claus E.B. Schildkraut J.M. Thompson W.D. Risch N.J. The genetic attributable risk of breast and ovarian cancer Cancer 77 1996 2318-2324
16. Couch F.J. Weber B.L. Breast cancer In Vogelstein B. Kinzler K.W. (Eds.), The genetic basis of human cancer 1998 537-563 McGraw-Hill New York
17. Srivastava A. McKinnon W. Wood M. Risk of breast and ovarian cancer in women with strong family histories Oncology 15 2001 889-902
18. Slattery M.L. Kerber R.A. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database JAMA 270 1993 1563-1568
19. Miki Y. Swensen J. Shattuck-Eidens D. Futreal P.A. Harshman K. Tavtigian S. et al. A strong candidate for the breast cancer and ovarian cancer susceptibility gene BRCA1 Science 266 1994 66-71
20. Wooster R. Bignell G. Lancaster J. Swift S. Seal S. Mangion J. et al. Identification of the breast cancer susceptibility gene BRCA2 Nature 378 1995 789-792
21. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2 Cell 108 2002 171-182
22. Eeles R. Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers Breast Cancer Res 2 2000 283-290
23. Ford D. Easton D.F. Bishop D.T. Narod S.A. Goldgar D.E. Risks of cancer in BRCA1-mutation carriers Lancet 343 1994 692-695
24. Balter M. Transatlantic war over BRCA1 patent Cancer Res 292 2001 1818
25. Peterson E.A. Milliron K.J. Lewis K.E. Goold S.D. Merajver S.D. Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population Cancer Epidemiol Biomarkers Prev 11 2002 79-87
26. Reynolds T. NCI-Myriad agreement offers BRCA testing at reduced cost J Natl Cancer Inst 92 2000 596
27. Chaliki H. Loader S. Levenkron J.C. Logan-Young W. Hall W.J. Rowley P.T. Women's receptivity to testing for a genetic susceptibility to breast cancer Am J Public Health 85 1995 1133-1135
28. Lerman C. Seay J. Balshem A. Audrain J. Interest in genetic testing among first-degree relatives of breast cancer patients Am J Med Genet 57 1995 385-392
29. Struewing J.P. Lerman C. Kase R.G. Giambarresi T.R. Tucker M.A. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families Cancer Epidemiol Biomarkers Prev 4 1995 169-173
30. Botkin J.R. Smith K.R. Croyle R.T. Baty B.J. Wylie J.E. Dutson D. et al. Genetic testing for a BRCA1 mutation: Prophylactic surgery and screening behavior in women 2 years post testing Am J Med Genet 118A 2003 201-209
31. Lerman C. Narod S. Schulman K. Hughes C. Gomez-Caminero A. Bonney G. et al. BRCA1 testing in families with hereditary breast-ovarian cancer: A prospective study of patient decision making and outcomes JAMA 275 1996 1885-1892
32. Gwyn K. Vernon S.W. Conoley P.M. Intention to pursue genetic testing for breast cancer among women due for screening mammography Cancer Epidemiol Biomarkers Prev 12 2003 96-102
33. Press N.A. Yasui Y. Reynolds S. Durfy S.J. Burke W. Women's interest in genetic testing for breast cancer susceptibility may be based on unrealistic expectations Am J Med Genet 99 2001 99-110
34. American Cancer Society Breast cancer facts & figures 2003-2004 [Internet] 2003 American Cancer Society
35. National Cancer Institute Cancer facts [Internet] 2002 National Cancer Institute
36. Antoniou A. Pharoah P. Narod S. Risch H. Eyfjord J. Hopper J. et al. Average risks of breast and ovarian cancer associated with BRCA1 and BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies Am J Hum Genet 72 2003 1117-1130
37. King M.C. Marks J.H. Handell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science 302 2003 643
38. Verhoog L.C. Brekelmans C.T. Seynaeve C. van den Bosch L.M. Dahmen G. van Geel A.N. et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 Lancet 351 1998 316-321
39. Easton D.F. Ford D. Bishop D.T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium Am J Hum Genet 56 1995 265-271
40. Breast Cancer Linkage Consortium Cancer risks in BRCA2 mutation carriers J Natl Cancer Inst 91 1999 1310-1316
41. Verhoog L.C. Brekelmans C.T. Seynaeve C. Dahmen G. van Geel A.N. Bartels C.C. et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2 J Clin Oncol 17 1999 3396-3402
42. Hahn S.A. Greenhalf B. Ellis I. Sina-Frey M. Rieder H. Korte B. et al. BRCA2 germline mutations in familial pancreatic carcinoma J Natl Cancer Inst 95 2003 214-221
43. Murphy K.M. Brune K.A. Griffin C. Sollenberger J.E. Petersen G.M. Bansal R. et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17% Cancer Res 62 2002 3789-3793
44. Gail M.H. Brinton L.A. Byar D.P. Corle D.K. Green S.B. Schairer C. Mulvihill J.J. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually J Natl Cancer Inst 81 1989 1879-1986
45. Costantino J.P. Gail M.H. Pee D. Anderson S. Redmond C.K. Benichou J. Wieand H.S. Validation studies for models projecting the risk of invasive and total breast cancer incidence J Natl Cancer Inst 91 1999 1541-1548
46. Claus E.B. Risch N. Thompson W.D. Autosomal dominant inheritance of early-onset breast cancer: Implications for risk prediction Cancer 73 1994 643-651
47. Berry D.A. Parmigiani G. Sanchez J. Schildkraut J. Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history J Natl Cancer Inst 8 1997 227-238
48. Parmigiani G. Berry D. Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2 Am J Hum Genet 62 1998 145-158
49. Berry D.A. Iversen E.S. Gudbjartsson D.F. Hiller E.H. Garber J.E. Peshkin B.N. Lerman C. et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes J Clin Oncol 20 2002 2701-2712
50. Claes E. Evers-Kiebooms G. Boogaerts A. Decruyenaere M. Denayer L. Legius E. Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients Am J Med Genet 116A 2003 11-19
51. Hughes C. Lerman C. Schwartz M. Peshkin B.N. Wenzel L. Narod S. et al. All in the family: Evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results Am J Med Genet 107 2002 143-150
52. Smith K.R. West J.A. Croyle R.T. Botkin J.R. Familial context of genetic testing for cancer susceptibility: Moderating effect of siblings' test results on psychological distress one to two weeks after BRCA1 mutation testing Cancer Epidemiol Biomarkers Prev 4 1999 385-392
53. Lynch H.T. Lemon S.J. Durham C. Tinley S.T. Connolly C. Lynch J.F. et al. A descriptive study of BRCA1 testing and reactions to disclosure of test results Cancer 79 1997 2219-2228
54. Thompson H.S. Valdimarsdottir H.B. Duteau-Buck C. Guevarra J. Bovbjerg D.H. Richmond-Avellaneda C. et al. Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women Cancer Epidemiol Biomarkers Prev 11 2002 1579-1585
55. d'Agincourt-Canning L. Experiences of genetic risk: Disclosure and the gendering of responsibility Bioethics 15 2001 231-247
56. Bredart A. Autier P. Riccardo A. Audisio A. Geraghty J.G. Psychosocial dimensions of BRCA testing: An overshadowed issue Eur J Cancer Care 10 2001 96-109
57. Croyle R.T. Smith K.R. Botkin J.R. Baty B. Nash J. Psychological responses to BRCA1 mutation testing: Preliminary findings Health Psychol 16 1997 63-72
58. Meiser B. Butow P. Friedlander M. Barratt A. Schnieden V. Watson M. et al. Psychological impact of genetic testing in women from high-risk breast cancer families Eur J Cancer 38 2002 2025-2031
59. Pasacreta J.V. Jacobs L. Cataldo J.K. Genetic testing for breast and ovarian cancer risk: The psychosocial issues Am J Nurs 102 2002 40-47
60. Watson M. Lloyd S. Davidson J. Meyer L. Eeles R. Ebbs S. Murday V. The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer Br J Cancer 79 1999 868-874
61. Lerman C. Croyle R.T. Tercyak K.P. Hamann H. Genetic testing: Psychological aspects and implications J Consult Clin Psychol 70 2002 784-797
62. Appleton S. Fry A. Rees G. Rush R. Cull A. Psychosocial effects of living with an increased risk of breast cancer: An exploratory study using telephone focus groups Psychooncology 9 2000 511-521
63. American Society of Clinical Oncology (ASCO) American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility J Clin Oncol 21 2003 1-10
64. Pinsky L. Culver J. Hull J. Levy-Lahad E. Daly M. Burke W. Gene scene. Why should primary care physicians know about breast cancer genetics West J Med 175 2001 168-174
65. Hartmann L.C. Sellers T.A. Schaid D.J. Frank T.S. Soderberg C.L. Sitta D.L. et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers J Natl Cancer Inst 93 2001 1633-1637
66. Rebbeck T.R. Lynch H.T. Neuhausen S.L. Narod S.A. Van't Veer L. Garber J.E. et al. Prevention and Observation of Surgical End Points Study Group: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations N Engl J Med 346 2002 1616-1622
67. Tiller K. Meiser B. Butow P. Clifton M. Thewes B. Friedlander M. Tucker K. Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer: A prospective study Gynecol Oncol 86 2002 212-219
68. Liede A. Karlan B.Y. Baldwin R.L. Platt L.D. Kuperstein G. Narod S.A. Cancer incidence in a population of Jewish women at risk of ovarian cancer Clin Oncol 20 2000 1570-1577
69. Modugno F. Ovarian Cancer and High-Risk Women Sympo-sium Presenters Ovarian cancer and high-risk women-Implications for prevention, screening, and early detection Gynecol Oncol 91 2003 15-31
70. Haites N.E. The ethical management of genetic testing Eur J Cancer 39 2003 1339-1340
71. Surbone A. Ethical implications of genetic testing for breast cancer susceptibility Crit Rev Oncol Hematol 40 2001 149-157
72. Costalas J.W. Itzen M. Malick J. Babb J.S. Bove B. Godwin A.K. et al. Communication of BRCA1 and BRCA2 results to at-risk relatives: A cancer risk assessment program's experience Am J Med Genet 119C 2003 11-18
73. Dudok de Wit A.C. Tibbon A. Frets P.G. Meijers-Heijboer E.J. Devilee P. Kiljn J.G.M. BRCA1 in the family: A case description of the psychological implications Am J Med Genet 71 1997 63-71
74. Green R. Thomas A.M. Whose gene is it? A case discussion about familial conflict over genetic testing for breast cancer J Genet Couns 6 1997 245-254
75. Juengst E. Caught in the middle again: Professional ethical considerations in genetic testing for health risks Genet Test 1 1998 189-200